Stock Market Returns and Clinical Trial Results of Investigational Compounds: An Event Study Analysis of Large Biopharmaceutical Companies

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Hwang, Thomas J ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DRUG INDICATION; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; DRUG RESEARCH; ECONOMIC ASPECT; SENSITIVITY ANALYSIS; SOCIOECONOMICS; STOCK MARKET;

ALGORITHMS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; COMMERCE; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; HUMANS; INVESTMENTS; MODELS, ECONOMIC; UNITED STATES;

EID: 84881320765     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071966     Document Type: Article

References (47)

1. nnell JW, Blanckley A, Boldon H, Warrington B, (2012) Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 11: 191-200.
2. Getz KA, Wenger J, Campo RA, Seguine ES, Kaitin KI, (2008) Assessing the impact of protocol design changes on clinical trial performance. Am J Ther 15: 450-457.
3. Munos B, (2009) Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 8: 959-968.
4. Pammolli F, Magazzini L, Riccaboni M, (2011) The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 10: 428-438.
5. DiMasi JA, Feldman L, Seckler A, Wilson A, (2010) Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 87: 272-277.
6. Rang HP (2006) Drug discovery and development: technology in transition. Edinburgh: Churchill Livingstone/Elsevier.
7. Arrowsmith J, (2011) Trial watch: Phase II failures: 2008-2010. Nat Rev Drug Discov 10: 328-329.
8. Thomson Reuters (2012) CMR International Pharmaceutical R&D Factbook. Available: http://cmr.thomsonreuters.com/pdf/2012-cmr-factbook-exc_cbr-en.pdf. Accessed 2013 May 1.
9. Senard JM, Montastruc P, Herxheimer A, (1996) Early warnings about drugs-from the stock market. Lancet 347: 987-988.
10. Topol EJ, Blumenthal D, (2005) Physicians and the investment industry. JAMA 293: 2654-2657.
11. Benowitz S, (2002) Big business: when Wall Street and cancer research collide. J Natl Cancer Inst 94: 1352-1353.
12. Steinbrook R, (2005) Wall Street and clinical trials. N Engl J Med 353: 1091-1093.
13. Ferguson JR, (1997) Biomedical research and insider trading. N Engl J Med 337: 631-634.
14. Chan SH, Martin JD, Kensinger JW, (1990) Corporate research and development expenditures and share value. Journal of Financial Economics 26: 255-276.
15. Sharma A, Lacey N, (2004) Linking product development outcomes to market valuation of the firm: The case of the U.S. pharmaceutical industry. Journal of Product Innovation Management 21: 297-308.
16. Shortridge RT, (2004) Market valuation of successful versus non-successful R&D efforts in the pharmaceutical industry. Journal of Business Finance and Accounting 31: 1301-1325.
17. Overgaard CB, van den Broek RA, Kim JH, Detsky AS, (2000) Biotechnology stock prices before public announcements: evidence of insider trading? J Investig Med 48: 118-124.
18. Rothenstein JM, Tomlinson G, Tannock IF, Detsky AS, (2011) Company stock prices before and after public announcements related to oncology drugs. J Natl Cancer Inst 103: 1507-1512.
19. MacKinlay A, (1997) Event studies in economics and finance. Journal of Economic Literature 35: 13-39.
20. Campbell J, Lo A, MacKinlay A (1997) The econometrics of financial markets. Princeton: Princeton University Press.
21. Pérez-Rodríguez JV, González López-Valcárcel B, (2012) Does innovation in obesity drugs affect stock markets? An event study analysis. Gac Sanit 26: 352-359.
22. Panattoni LE, (2011) The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms. J Health Econ 30: 126-145.
23. Campbell C, Wasley C, (1993) Measuring security price performance using daily NASDAQ returns. Journal of Financial Economics 33: 73-92.
24. Kolari JW, Pynnonen S, (2011) Nonparametric rank tests for event studies. Journal of Empirical Finance 18: 953-971.
25. Fidrmuc JP, Goergen M, Renneboog L, (2006) Insider trading, news releases, and ownership concentration. Journal of Finance 61: 2931-2973.
26. Bailey W, Karolyi GA, Salva C, (2006) The economic consequences of increased disclosure: Evidence from international cross-listings. Journal of Financial Economics 81: 175-213.
27. Cutler DM, Poterba JM, Summers LH, (1989) What moves stock prices? Journal of Portfolio Management 15: 4-12.
28. McQueen G, Roley VV, (1993) Stock prices, news, and business conditions. Review of Fin Studies 6: 683-707.
29. Chan WS, (2003) Stock price reaction to news and no-news: drift and reversal after headlines. Journal of Financial Economics 70: 223-260.
30. Vega C, (2006) Stock price reaction to public and private information. Journal of Financial Economics 82: 103-133.
31. Tetlock P, (2007) Giving content to investor sentiment: The role of media in the stock market. The Journal of Finance 62: 1139-1168.
32. Barber BM, Odean T, (2008) All that glitters: The effect of attention and news on the buying behavior of individual and institutional investors. Review of Financial Studies 21: 785-818.
33. Dellavigna S, Pollet J, (2011) Investor inattention and friday earnings announcements. Journal of Finance 64: 709-749.
34. Engelberg J, Parsons C, (2011) The causal impact of media in financial markets. Journal of Finance 66: 67-97.
35. Lillo F, Miccichè S, Tumminello M, Piilo J, Mantegna RN (2012) How news affect the trading behavior of different categories of investors in a financial market. arXiv1207.3300.
36. Preis T, Moat HS, Stanley HE, (2013) Quantifying trading behavior in financial markets using Google Trends. Sci Rep 3: 1684.
37. Da Z, Engelberg J, Gao PJ, (2011) In search of attention. Journal of Finance 56: 1461-1499.
38. Bordino I, Battiston S, Caldarelli G, Cristelli M, Ukkonen A, et al. (2012) Web search queries can predict stock market volumes. PLoS One 7: e40014.
39. Moat HS, Curme C, Avakian A, Kenett DY, Stanley HE, et al. (2013) Quantifying Wikipedia usage patterns before stock market moves. Sci Rep 3: 1801.
40. Bollen J, Mao H, Zeng X, (2011) Twitter mood predicts the stock market. Journal of Computational Science 2: 1-8.
41. Hisano R, Sornette D, Mizuno T, Ohnishi T, Watanabe T, (2013) High quality topic extraction from business news explains abnormal financial market volatility. PLoS One 8: e64846.
42. Joulin A, Lefevre A, Grunberg D, Bouchaud JP (2008) Stock price jumps: news and volume play a minor role. arXiv0803.1769.
43. Carpenter D (2010) Reputation and power: Organizational image and pharmaceutical regulation at the FDA. Princeton: Princeton University Press.
44. Dranove D, Olsen C, (1994) The economic side effects of dangerous drug announcements. Journal of Law & Economics 37: 323-348.
45. Lang L, Stulz R, (1992) Contagion and competitive intra-industry effects of bankruptcy announcements: an empirical analysis. Journal of Financial Economics 32: 45-60.
46. Rothfeld M, Bray C, Pulliam S (2012) Trading charges reach SAC. Wall Street Journal. Available: http://online.wsj.com/article/SB10001424127887323713104578130930796204500.html. Accessed 2013 May 1.
47. Armstrong D (2012) Drug stocks prey for insiders as industry resists change. Bloomberg. Available: http://www.bloomberg.com/news/2012-12-21/drug-stocks-prey-for-insiders-as-industry-resists-change.html. Accessed 2013 May 1.